Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

34.59 +0.23 (+0.67%)
Official Closing Price Updated: 6:30 PM EST, Nov 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,090,380
Open 34.39
Bid (Size) 34.60 (10)
Ask (Size) 34.68 (1)
Prev. Close 34.36
Today's Range 33.89 - 34.59
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga

Performance

YTD
-20.79%
-20.79%
1 Month
+4.28%
+4.28%
3 Month
+4.95%
+4.95%
6 Month
-21.21%
-21.21%
1 Year
-16.37%
-16.37%

More News

Read More
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Via Benzinga
After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US
Via Benzinga
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
Via Benzinga
GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations
Via Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
Via The Motley Fool
Dividend Income Update October 2022
Via Talk Markets
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Peering Into GSK's Recent Short Interest
Via Benzinga
Daily Stock Analysis: GSK plc
Via Talk Markets
Citing Efficacy, GSK Stops Two Pivotal UTI Antibiotic Trials Early
Via Benzinga
GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat
Via Investor's Business Daily
GSK Lifts Annual Outlook After Robust Vaccines, Specialty Medicine Sales In Q3
Via Benzinga
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Via Investor's Business Daily
GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care
Via Benzinga
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Via Talk Markets
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Via Investor's Business Daily
Moderna's Earnings Collapsed. Time to Sell?
Via The Motley Fool
GSK's Debt Overview
Via Benzinga
Downsizing At Twitter After Musk Takeover, Big Pharma Chains To Pay $14B In Opioid Claims, Tesla Shutters 1st Showroom In China: Top Stories Wednesday, Nov. 02
Via Benzinga
Recap: GSK Q3 Earnings
Via Benzinga
Earnings This Week: AMD, BP And PayPal
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.